Anti-CEA mAbs have potential as antibody-drug conjugates (ADCs), and labetuzumab govitecan (IMMU 130), an anti-CEA/SN-38 conjugate, displayed therapeutic activity in heavily pretreated patients with metastatic colorectal cancer [109]. Here, CEACAM5 is linked to metastatic colorectal cancer.